Clinical Research Directory
Browse clinical research sites, groups, and studies.
Empagliflozin Versus Non-SGLT2 Oral Drugs for Blood Pressure in Type 2 Diabetes
Sponsor: Dr. Zarmina Younes
Summary
This randomized controlled trial studied whether empagliflozin lowers blood pressure better than non-SGLT2 oral hypoglycemic treatment in adults with type 2 diabetes mellitus and hypertension. A total of 300 participants were assigned to 1 of 2 treatment groups and followed for 12 weeks. One group received empagliflozin and the other received non-SGLT2 oral therapy. Blood pressure was measured at baseline and again after 12 weeks to compare the effect of treatment on systolic and diastolic blood pressure.
Official title: Comparison of Mean Blood Pressure in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin Versus Non-SGLT2 Oral Hypoglycemic Agents: A Randomized Controlled Trial
Key Details
Gender
All
Age Range
20 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2025-06-09
Completion Date
2025-11-08
Last Updated
2026-04-21
Healthy Volunteers
No
Conditions
Interventions
Empagliflozin
Empagliflozin 10 mg once daily for the first 4 weeks, increased to 25 mg once daily until week 12.
Metformin
Metformin 500 mg twice daily for 12 weeks.
Locations (1)
Shahida Islam Medical College, Lodhran
Lodhran, Punjab Province, Pakistan